Latest Conference Articles

December 13th 2021, 7:20pm

ASH Annual Meeting and Exposition

Comparative data from the phase 1 CARTITUDE-1 trial and the real-world LocoMMotion study demonstrated that ciltacabtagene autoleucel bested standard options for patients with triple-class exposed multiple myeloma.

December 13th 2021, 7:20pm

ASH Annual Meeting and Exposition

Selinexor combined with venetoclax demonstrated efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma cell lines with t(11;14), according to small study results that were presented during the 2021 ASH Annual Meeting.

December 13th 2021, 6:44pm

ASH Annual Meeting and Exposition

The first-in-class monoclonal antibody treatment for acute graft-versus-host disease had durable responses and tolerability for patients.

December 13th 2021, 6:40pm

ASH Annual Meeting and Exposition

Glofitamab, an investigational CD20xCD3 bispecific antibody, induced high response rates as monotherapy or in combination with obinutuzumab in patients with multiple relapsed or refractory follicular lymphoma.

December 13th 2021, 6:13pm

ASH Annual Meeting and Exposition

Treatment with lisocabtagene maraleucel demonstrated durable responses in patients with relapsed/refractory large B-cell lymphomas.

December 13th 2021, 6:03pm

ASH Annual Meeting and Exposition

Cost and personal time spent on managing adverse effects for treatment with ibrutinib, acalabrutinib, or venetoclax could inform decision-making strategies for treatment selection in patients with chronic lymphocytic leukemia.

December 13th 2021, 4:25pm

ASH Annual Meeting and Exposition

Naratuximab emtansine plus rituximab had promising response rates while also improving patient well-being when used to treat diffuse relapsed/refractory large B-cell lymphoma and other non-Hodgkin B-cell lymphomas.

December 13th 2021, 12:34am

ASH Annual Meeting and Exposition

The addition of ublituximab and umbralisib to ibrutinib produced deep remissions with favorable tolerability in patients with chronic lymphocytic leukemia who previously received ibrutinib and still had detectable minimal residual disease.

December 13th 2021, 12:30am

ASH Annual Meeting and Exposition

Axicabtagene ciloleucel led to a 60% improvement in event-free survival compared with standard-of-care chemotherapy as second-line treatment for patients with relapsed/refractory large B-cell lymphoma.

December 12th 2021, 11:19pm

ASH Annual Meeting and Exposition

Ciltacabtagene autoleucel demonstrated a significant advantage over physician’s choice of treatment with regard to overall survival, progression-free survival, time to next treatment, and overall response rate, underscoring its potential for use in patients with triple-class relapsed/refractory multiple myeloma.

December 12th 2021, 10:18pm

ASH Annual Meeting and Exposition

Frederick Locke, MD, discusses the results of the phase 3 ZUMA-7 trial in patients with large B-cell lymphoma that were presented at the 2021 ASH Annual Meeting & Exposition.

December 12th 2021, 9:46pm

ASH Annual Meeting and Exposition

Extended induction and consolidation therapy with daratumumab plus ixazomib, lenalidomide, and dexamethasone led to deepening rates of minimal residual disease for patients with standard-risk, transplant-eligible newly diagnosed multiple myeloma.

December 12th 2021, 8:39pm

ASH Annual Meeting and Exposition

The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.

December 12th 2021, 8:08pm

ASH Annual Meeting and Exposition

Minimal residual disease, assessed through next-generation sequencing was found to inform treatment selection and duration with daratumumab plus carfilzomib, lenalidomide, and dexamethasone following autologous transplant in patients with newly diagnosed multiple myeloma.

December 12th 2021, 7:02pm

ASH Annual Meeting and Exposition

Axicabtagene ciloleucel, an autologous anti-CD19 CAR T-cell therapy, resulted in clinically meaningful improvement in quality of life at day 100 compared with standard of care as a second-line treatment of patients with relapsed/refractory large B-cell lymphoma.

December 12th 2021, 6:33pm

ASH Annual Meeting and Exposition

Weekly selinexor plus bortezomib and dexamethasone represents a favorable option for patients with multiple myeloma and any cytogenetic profile, based on comparable objective responses rates and progression-free survival results from 2 clinical trials.

December 12th 2021, 6:29pm

ASH Annual Meeting and Exposition

The addition of eryaspase to chemotherapy demonstrated biological efficacy and tolerability in patients with acute lymphoblastic leukemia who are at risk of developing hypersensitivity reactions to Escherichia coli–derived pegylated asparaginase.

December 12th 2021, 6:18pm

ASH Annual Meeting and Exposition

Tisagenlecleucel demonstrated encouraging real-world efficacy and a favorable safety profile that was consistent with findings from the pivotal phase 2 JULIET trial in patients with relapsed/refractory diffuse large B-cell lymphoma or high-grade B-cell lymphoma.

December 12th 2021, 6:06pm

ASH Annual Meeting and Exposition

Asciminib demonstrated a consistent improvement in major molecular response rate and depth of response vs bosutinib in patients with chronic-phase chronic myeloid leukemia without any new or worsening adverse effects.

December 12th 2021, 5:52pm

ASH Annual Meeting and Exposition

Ibrutinib plus rituximab and mini-CHOP failed to demonstrate a statistically significant improvement in overall survival at 2 years but led to an improvement in progression-free survival, quality of life, and function in elderly patients with diffuse large B-cell lymphoma.